$AMPH News

Amphastar Pharmaceuticals (AMPH) Stock Looks About Right After A 42% Slide

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Amphastar: 2 Years Since My Last Hold Call, I Remain On The Sidelines

3 Reasons to Avoid AMPH and 1 Stock to Buy Instead

Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group

Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?

Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate

The Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call

Amphastar (AMPH) Q2 2026 Earnings Call Transcript

AMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results

Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Amphastar Pharmaceuticals Q2 Earnings Call Highlights

Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026